Literature DB >> 2070204

Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.

P Whelan1, J A Cumming, W H Garvie, T B Hargreave, D Kirk, D W Newling, M R Robinson, P H Smith.   

Abstract

Forty patients with multiple recurrent superficial bladder tumours received an 8-week course of weekly instillations of 4' epirubicin 30 mg in 50 ml saline. The overall response rate was 58% and side effects were minimal.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2070204     DOI： 10.1111/j.1464-410x.1991.tb15223.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


  5 in total

1.  Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory. Nara Uro-oncology Research Group. (NUORG).

Authors:  Y Hirao; S Ozono; H Momose; E Okajima; T Hiramatsu; K Yoshida; S Fukushima; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.

Authors:  H Eto; Y Oka; K Ueno; I Nakamura; K Yoshimura; S Arakawa; S Kamidono; S Obe; T Ogawa; G Hamami
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Intravesical epirubicin in the prophylaxis of superficial bladder cancer.

Authors:  F Sengör; M Beysel; K Erdoğan; A Erol; D Tuzluoğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 5.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.